uric acid has been researched along with Blood Coagulation Disorders in 19 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Blood Coagulation Disorders: Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Laboratory tests revealed liver dysfunction, coagulopathy, hypoglycemia, hypoproteinemia, leukocytosis, and elevated creatinine and uric acid levels." | 4.12 | Timely identification and successful treatment of acute fatty liver of pregnancy without obvious clinical symptoms: Case reports. ( Cao, W; Chen, T; Geng, Y; Jiang, W; Wang, Q; Wang, X; Xie, B, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (73.68) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, W | 1 |
| Chen, T | 1 |
| Jiang, W | 1 |
| Geng, Y | 1 |
| Xie, B | 1 |
| Wang, Q | 1 |
| Wang, X | 1 |
| Yamada, T | 2 |
| Ishikawa, S | 1 |
| Kataoka, S | 1 |
| Uda, T | 1 |
| Iinuma, Y | 1 |
| Hattori, R | 1 |
| Morikawa, M | 1 |
| Kaneuchi, M | 1 |
| Minakami, H | 1 |
| Anagnostis, P | 1 |
| Athyros, VG | 1 |
| Tziomalos, K | 1 |
| Karagiannis, A | 1 |
| Mikhailidis, DP | 1 |
| Stewart, K | 1 |
| Mitchell, MA | 1 |
| Norton, T | 1 |
| Krecek, RC | 1 |
| Păunescu-Podeanu, A | 1 |
| Ciorapciu, S | 1 |
| Costescu, M | 1 |
| Demirian, H | 1 |
| Andronescu, M | 1 |
| Gorcea, V | 1 |
| Rubingher, L | 1 |
| Stănică, V | 1 |
| Redman, CW | 1 |
| Denson, KW | 1 |
| Beilin, LJ | 1 |
| Bolton, FG | 1 |
| Stirrat, GM | 1 |
| Heller, W | 1 |
| Domres, B | 1 |
| Hausdörfer, J | 1 |
| Veihelmann, D | 1 |
| Giler, S | 1 |
| Urca, I | 1 |
| Sperling, O | 1 |
| Barlattani, M | 1 |
| Messina, B | 1 |
| Ideura, T | 1 |
| Yoshimura, A | 1 |
| Valentin, B | 1 |
| Laffargue, F | 1 |
| Daures, JP | 1 |
| Hedon, B | 1 |
| Denjean, R | 1 |
| Dujols, P | 1 |
| Loubatières, Y | 1 |
| Viala, JL | 1 |
| Brittinger, G | 1 |
| Burmeister, H | 1 |
| Ohlmeier, H | 1 |
| Baethke, R | 1 |
| Sims, EA | 1 |
| Pinkhas, J | 1 |
| Chivot, JJ | 1 |
| Michel, H | 1 |
| Caen, J | 1 |
| Aur, RJ | 1 |
| Simone, JV | 1 |
| Pratt, CB | 1 |
| Boettcher, WG | 1 |
| Bonfiglio, M | 1 |
| Hamilton, HH | 1 |
| Sheets, RF | 1 |
| Smith, K | 1 |
| Mingers, A | 1 |
| Ströder, J | 1 |
| Pavel, W | 1 |
| Göltner, E | 1 |
| Scheitza, E | 1 |
| Hooey, MA | 1 |
| Crookston, JH | 1 |
| Squires, AH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals[NCT01419535] | Phase 1/Phase 2 | 19 participants (Actual) | Interventional | 2011-11-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The adipose tissue insulin resistance index (Adipo-IR), a surrogate measure for fasting adipose-tissue insulin resistance, was calculated as the product of fasting insulin and fasting free fatty acids (FFA) (NCT01419535)
Timeframe: 9 days
| Intervention | mmol/l·μU/l (Mean) |
|---|---|
| Post-mifepristone | 49.9 |
| Post-placebo | 65.5 |
The Adipo-SI was calculated as ratio of the slope of the linear decrease in natural log transformed FFA [Ln (FFA) slope] during the first 90 minutes of the FSIVGTT and the area under the curve (AUC) of insulin during that 90-minute period (AUC Insulin 0-90 min). (NCT01419535)
Timeframe: 9 days
| Intervention | ln(mmol /uU/mL*min)*10^8 (Mean) |
|---|---|
| Post-mifepristone | 61.7 |
| Post-placebo | 42.8 |
Fasting insulin after study agent administration compared to baseline (NCT01419535)
Timeframe: 9 days
| Intervention | pmol/L (Mean) |
|---|---|
| Post-mifepristone | 95.6 |
| Post-placebo | 142.8 |
fasting plasma glucose after study agent compared to baseline (NCT01419535)
Timeframe: Nine days
| Intervention | mg/dL (Mean) |
|---|---|
| Post-mifepristone | 100.4 |
| Post-placebo | 107.8 |
insulin sensitivity index based on the effect of insulin on glucose during frequently sampled intravenous glucose tolerance test (FSIVGTT) (NCT01419535)
Timeframe: Nine days
| Intervention | min-1·μU·ml-1 (Mean) |
|---|---|
| Post-mifepristone | 1.49 |
| Post-placebo | 1.41 |
HOMA-IR is an index of insulin resistance, measured as glucose in mmol/L x insulin in mIU/mL)/22.5. HOMA-IR > 2.5 indicates insulin resistance. (NCT01419535)
Timeframe: 9 days
| Intervention | units on a scale (Mean) |
|---|---|
| Post-mifepristone | 3.58 |
| Post-placebo | 5.78 |
3 reviews available for uric acid and Blood Coagulation Disorders
| Article | Year |
|---|---|
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipokines; Birth Weight; Blood Coagulation Disorders; | 2009 |
[Non-specific basic therapy of leukemias and their complications].
Topics: Acute Disease; Adrenal Cortex Hormones; Allopurinol; Anemia; Autoimmune Diseases; Blood Coagulation | 1974 |
Pre-eclampsia and related complications of pregnancy.
Topics: Adult; Aldosterone; Angiotensin II; Blood Coagulation Disorders; Catecholamines; Diagnosis, Differen | 1970 |
16 other studies available for uric acid and Blood Coagulation Disorders
| Article | Year |
|---|---|
Timely identification and successful treatment of acute fatty liver of pregnancy without obvious clinical symptoms: Case reports.
Topics: Adult; Blood Coagulation Disorders; Fatty Liver; Female; Humans; Hypoglycemia; Infant, Newborn; Preg | 2022 |
Coagulation/fibrinolysis and laboratory characteristics of pregnant women with severely depressed antithrombin activity.
Topics: Antithrombins; Blood Coagulation Disorders; Creatinine; Female; Fibrin Fibrinogen Degradation Produc | 2013 |
Measuring the level of agreement in hematologic and biochemical values between blood sampling sites in leatherback sea turtles (Dermochelys coriacea).
Topics: Animals; Aspartate Aminotransferases; Beta-Globulins; Blood Coagulation Disorders; Blood Glucose; Bl | 2012 |
[Arguments for the pluripathogenesis of atherosclerosis].
Topics: Adult; Aged; Arteriosclerosis; Blood Coagulation Disorders; Carbohydrate Metabolism; Cholesterol; Fe | 1967 |
Factor-VIII consumption in pre-eclampsia.
Topics: Adult; Antigens; Blood Coagulation Disorders; Factor VIII; Female; Fetal Death; Humans; Pre-Eclampsi | 1977 |
[Metabolic studies in traumatic shock considering therapeutic measures].
Topics: Blood Cell Count; Blood Coagulation Disorders; Blood Platelets; Brain Injuries; Carbohydrate Metabol | 1979 |
Elevated serum urate and normocholesterolemia in patients with thromboangiitis obliterans.
Topics: Arteriosclerosis; Blood Coagulation Disorders; Blood Viscosity; Cholesterol; Humans; Male; Thromboan | 1978 |
[Hyperuricemia syndrome and blood coagulation disorder: effects of crenotherapy].
Topics: Blood Coagulation Disorders; Gout; Health Resorts; Humans; Mineral Waters; Syndrome; Uric Acid | 1975 |
[Kidney diseases associated with pregnancy toxemia].
Topics: Blood Coagulation Disorders; Female; Humans; Hypertension; Kidney; Kidney Diseases; Pre-Eclampsia; P | 1992 |
[Evaluation of the clinical and biologic means of assessing fetal prognosis in pregnancy toxemias. Apropos of 223 cases].
Topics: Blood Coagulation Disorders; Blood Pressure; Body Weight; Circadian Rhythm; Edema; Female; Fetal Dis | 1985 |
[Side effects and complication possibilities following high-dosage furosemide treatment].
Topics: Adult; Aged; Alkalosis; Blood Coagulation Disorders; Blood Glucose; Dehydration; Drug Eruptions; Ear | 1972 |
Adenosine metabolism in plasma and platelets. IV. Elevated plasmatic adenosine deaminase activity, impaired platelet 14C-adenosine incorporation and hemostatic dysfunction in chronic myeloid leukemia.
Topics: Adenine Nucleotides; Allopurinol; Aminohydrolases; Blood Cell Count; Blood Coagulation Disorders; Bl | 1970 |
Successful remission induction in children with acute lymphocytic leukemia at high risk for treatment failure.
Topics: Amylases; Asparaginase; Blood Coagulation Disorders; Child; Child, Preschool; Daunorubicin; Female; | 1971 |
Non-traumatic necrosis of the femoral head. I. Relation of altered hemostasis to etiology.
Topics: Alcohol Drinking; Blood Coagulation Disorders; Blood Coagulation Tests; Blood Platelet Disorders; Fe | 1970 |
[Coagulation factors before and after peritoneal dialysis in chronic uremia].
Topics: Adolescent; Adult; Aged; Blood Coagulation; Blood Coagulation Disorders; Blood Coagulation Factors; | 1969 |
Myeloproliferative disease complicated by megaloblastic anemia and hyperuricemia.
Topics: Anemia, Macrocytic; Blood; Blood Coagulation Disorders; Busulfan; Enzyme Therapy; Epistaxis; Female; | 1965 |